勃林格殷格翰的思力华在中国上市了吗？

(Respimat) is a product independently developed by Boehringer Ingelheim. The drug was first officially launched in 2002 and landed in China in 2006. So far, Boehringer Ingelheim's Slivar has been on the market in China for 14 years. Not only that, the drug has also been included in the national medical insurance catalog, bringing benefits to patients when purchasing drugs and treatment.

In order to allow patients to receive and benefit from the treatment of Siliva, Boehringer Ingelheim continues to develop new products and try various product combinations. At present, the main drugs sold in my country are Silivar, Aitrole, and Cobite (mainly used to treat chronic obstructive pulmonary disease), Muscotan (mainly used to protect the lungs and can eliminate phlegm), Senfuluo (mainly used to treat Parkinson's disease), Mecasol, Mejisol (mainly used to treat hypertension), Aitongli (mainly used to treat acute myocardial infarction and ischemic stroke), and Mobico (can relieve inflammation and pain).

In addition to the above products, there are also diabetes, anti-tumor and atrial fibrillation stroke prevention products that will be launched soon, making Boehringer Ingelheim’s product line in China richer and more diversified. It can be seen that the products launched by Boehringer Ingelheim in China cover a variety of therapeutic areas, such as central nervous system diseases, metabolic diseases, cardiovascular diseases, immunity and inflammation, etc. Although Boehringer Ingelheim is a multinational pharmaceutical company, it has provided practical assistance in formulating disease treatment plans and building medical cooperation platforms.

In the case of Boehringer Ingelheim's Spirax, the 2008 and 2011 UPLIFT and POET studies confirmed Spirava's leadership in the treatment of chronic obstructive pulmonary disease (COPD). Siliva has been registered and marketed in more than 100 countries around the world. In 2012, global sales reached US$4.5 billion. It has been verified by 25 million patients annually, accounting for 70% of the company's total sales. Silihua has professional craftsmanship, excellent quality, and excellent efficacy. Therefore, the 2013 GOLD guideline recommended it as the first choice for the treatment of stable COPD.

Recommended hot articles: /newsDetail/92319.html